ArticleOPEN ACCESS

First targeted therapy in multiple myeloma

Blood
DOI: 10.1182/blood-2017-09-805341
6Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, Kumar et al and Moreau et al both report venetoclax to be safe and effective in the treatment of multiple myeloma (MM), the second most common hematological malignancy.1,2

Cite

CITATION STYLE

APA

Kortüm, K. M., & Einsele, H. (2017, November 30). First targeted therapy in multiple myeloma. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2017-09-805341

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free